oncology
Illumina forms spin-off to develop cancer detection test
January 14, 2016Research and Development Cancer, Illumina, cancer detection, gene sequencing, liquid biospy, oncology
Global gene sequencing company Illumina has won over $100 million in investment from high-profile investors, to create a company “to …
MSD to acquire Scottish firm IOmet Pharma
January 12, 2016Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology
US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology
Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …
100 year old chemical could be the future of cancer treatment
December 23, 2015Research and Development Cancer, PV-10, Peter Culpepper, Provectus, Rose Bengal, oncology
Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …
More breakthroughs in cancer pose the question: Who pays for them?
December 16, 2015Research and Development Cancer, drug access, immunotherapy, oncology
The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
Takeda reveals five-year Adcetris survival data
December 6, 2015Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology
Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Clinigen launches UK managed access program for Takeda’s ixazomib
November 30, 2015Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology
Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …
Bayer and Novartis to debut new data at ASH 2015
November 30, 2015Research and Development, Sales and Marketing American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology
Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …
Lilly cancer drug gets US approval
November 26, 2015NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology
Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …
Challenges in oncology R&D – part 2
November 25, 2015Manufacturing and Production, Research and Development R&D, Takeda, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
Challenges in oncology R&D
November 18, 2015Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
